Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 653 trials

Propofol Injection Pain Study

We are investigating whether propofol causes more pain than a placebo in healthy adults. This study aims to better understand pain levels during and after the injection.

Pain Relief1-2 yearsEfficacy phase (II)Standard MedicinesInternal MedicineOtolaryngologyPsychiatry

Rheumatoid Arthritis: Adalimumab Tapering Study

We are investigating the lowest effective dose of adalimumab for patients with rheumatoid arthritis in remission. The study also looks at how well patients tolerate the treatment and the development of antibodies.

Rheumatoid Arthritis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineRheumatology

Spinocerebellar Ataxia and Huntington’s Disease: VO659 Treatment

We are investigating the safety of a new treatment given through the spine for people with spinocerebellar ataxia types 1 and 3, and Huntington’s disease. This study aims to understand how the body processes the medication.

Spinocerebellar Ataxia Types 1, 3 and Huntington's Disease1-2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteNeurology

Breast Cancer: Patritumab Deruxtecan with Pembrolizumab

We are studying a new treatment combination for high-risk early-stage breast cancer patients to see if it improves tumor response compared to standard chemotherapy. This trial will help us understand the safety and effectiveness of this new approach.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Fibrotic Lung Disease: Wharton's Jelly Stem Cells

We are studying the safety and effects of a stem cell treatment for people with fibrotic interstitial lung diseases. This research aims to see if it can improve lung function and quality of life.

Interstitial Lung Disease1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicinePulmonology

Epcoritamab for Relapsed Large B-Cell Lymphoma

We are studying the effectiveness of Epcoritamab as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma. This trial aims to see how well it works and how safe it is compared to other treatments.

Diffuse Large B-cell Lymphoma1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Low Ovarian Reserve: Factor-Rich Plasma Treatment

We are studying whether Factor-Rich Plasma injections can improve ovarian function and increase pregnancy rates in women with low ovarian reserve. This trial will also monitor any potential complications from the treatment.

Low Ovarian Reserve1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal Medicine

Systemic Sclerosis: Efgartigimod PH20 SC Study

We are testing a new treatment for adults with systemic sclerosis to see if it improves skin symptoms and overall health compared to a placebo. The study will also look at safety and how well the treatment works.

Systemic Sclerosis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Multiple Sclerosis: Ocrelizumab Serum Monitoring

We are studying how blood levels of ocrelizumab affect treatment outcomes in people with relapsing-remitting and primary progressive multiple sclerosis. This research may help personalize therapy and improve patient care.

Multiple Sclerosis1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurology

Small Cell Lung Cancer: 68Ga-EVG321 Diagnostic Study

We are studying a new diagnostic agent to see how it spreads in the body of patients with small cell lung cancer. The trial also looks at its safety and how the body processes it.

Small Cell Lung Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease: CTX001 Treatment

We are studying a new gene therapy using modified stem cells for adolescents and adults with transfusion-dependent β-thalassemia or severe sickle cell disease. The goal is to evaluate its effectiveness and safety in improving their condition.

Transfusion-dependent β-thalassemiaSevere sickle cell disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematology

Arrhythmogenic Cardiomyopathy: Atorvastatin Study

We are evaluating whether atorvastatin can help slow down heart function decline in people with Arrhythmogenic Cardiomyopathy. The study also looks at its safety and effects on heart-related markers.

Arrhythmogenic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Avacopan for Children with Active ANCA-associated Vasculitis

We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.

ANCA-associated Vasculitis1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineRheumatology

Thyroid Eye Disease: TOUR006 Treatment Study

We are investigating whether the new treatment TOUR006 can reduce eye bulging in adults with thyroid eye disease. Participants will receive either the treatment or a placebo to compare effects.

Thyroid Eye Disease1-2 yearsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Lung Cancer: Pembrolizumab and Lenvatinib Combination Therapy

We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.

Non-Small-Cell Lung Cancer1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPulmonology

Advanced Solid Tumors: OSE-279 Treatment Study

We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.

Stage IV Non-Small Cell Lung CancerAdvanced Solid TumorsLymphoma1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology